Metabolomic study on the mechanism of asthenospermia induced by tripterygium glycosides and ornidazole in rats via GC-MS approach

Abstract

Abstract:

AIM: To explore the protential biomarkers and the mechanism of asthenospermia induced by tripterygium glycosides (TG) and ornidazole (ONZ), respectively, relying on gas chromatography-mass spectrometry (GC-MS)-based metabolomics. METHODS: Wistar rats were orally administrated with TG(40 mg·kg-1·d-1) and ONZ (400 mg·kg-1·d-1) for 30 days, respectively. Serum and epididymal fluid samples were collected every two weeks. A metabolomic approach based on GC-MS was employed to identify endogenous metabolites in serum and epididymal fluid samples, respectively. Data acquired were further evaluated by multivariate statistical analysis and a partial least squares discriminant analysis (PLS-DA) was applied to finding potential biomarkers.RESULTS:PLS-DA clearly profiled a time-dependent alternation of metabolic phenotype of serum and epididymal fluid samples. The clear classifications between the normal and TG group, the normal and ONZ group as well as TG group and ONZ group were achieved. And some significant metabolites were successfully filtered. The levels of lysine, threonine and some other amino acids in serum were higher in the TG-treated rats than those in the normal rats. In the ONZ-treated rats, concentrations of amino acids in serum were declined. In addition, the level of butanedioic acid was increased in epididymal fluid of TG-treated rats, while the levels of urea, cholesterol, inositol, etc were varied in an opposite manner. Significant changes were observed in the levels of dihydroxyacetone phosphate and ribulose-5-phosphate in epididymal fluid of ONZ-treated rats, compared with the normal rats. CONCLUSION: The metabolomics technology as a high-efficiency tool can be used to distinguish the difference between TG-induced and ONZ-induced asthenospermia in rats. More importantly, TG-induced and ONZ-induced asthenospermia may have different etiology due to disturbing different endogenous metabolic pathways.

Key words: metabonomics, asthenospermia, tripterygium glycosides, ornidazole, GC-MS

CLC Number:

R965.2

GU Huiqing, ZHAO Ang, ZHOU Yanfen, LI Jing, FAN Li, WANG Cong, GUO Suhan, WANG Yu, ZHANG Qi, MA Bo. Metabolomic study on the mechanism of asthenospermia induced by tripterygium glycosides and ornidazole in rats via GC-MS approach[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 721-730.

References

［1］Imamovic KS, Pinter B. Review of clinical trials on effects of oral antioxidants on basic semen and other parameters in idiopathic oligoasthenoteratozoospermia［J］. Biomed Res Int, 2014,2014:426951.
［2］Chohan KR, Griffin JT, Lafromboise M, et al. Comparison of chromatin assays for DNA fragmentation evaluation in human sperm［J］. J Androl, 2006,27(1):53-59.
［3］Jurewicz J, Radwan M, Sobala W, et al. The relationship between exposure to air pollution and sperm disomy［J］. Environ Mol Mutagen, 2015,56(1):50-59.
［4］Cavallini G. Male idiopathic oligoasthenoteratozoospermia［J］. Asian J Androl, 2006,8(2):143-157.
［5］Kamma JJ, Nakou M, Mitsis FJ. The clinical and microbiological effects of systemic ornidazole in sites with and without subgingival debridement in early-onset periodontitis patients［J］. J Periodontol, 2000,71(12):1862-1873.
［6］庞雪冰, 李红钢, 朱继望, 等. 奥硝唑对大鼠精子的影响及作用机制探讨［J］.中华男科学杂志,2005,11(1):26-28.
［7］Phillips BT, Gassei K, Orwig KE. Spermatogonial stem cell regulation and spermatogenesis［J］. Philos Trans R Soc Lond B Biol Sci, 2010,365(1546):1663-1678.
［8］景晓平, 丁樱, 何丽. 补肾中药对雷公藤多苷所致雄性幼鼠生殖损伤的保护作用及最终生育能力的影响［J］.中国实验方剂学杂志,2013,15(20):230-233.
［9］Li J, Hu Y, Zhang Q, et al. Strontium fructose 1, 6-diphosphate alleviate cyclophosphamide-induced oligozoospermia by improving antioxidant and inhibiting testicular apoptosis via FAS/FASL pathway［J］. Andrologia, 2015,47(9):995-1003.
［10］Castro-Santos P, Laborde CM, Díaz-Peha R. Genomics, proteomics and metabolomics: their emerging roles in the discovery and validation of rheumatoid arthritis biomarkers［J］. Clin Exp Rheumatol, 2015,33(2):279-286.
［11］Zhang Q, Wang G, A J, et al. Metabonomic profiling of diet-induced hyperlipidaemia in a rat model［J］. Biomarkers, 2010,15(3):205-216.
［12］Ma B, Liu J, Zhang Q, et al. Metabolomic profiles delineate signature metabolic shifts during estrogen deficiency-induced bone loss in rat by GC-TOF/MS［J］. PLoS One, 2013,8(2):e54965.
［13］涂佳玉, 阿基业, 王广基, 等. 通塞脉微丸干预缺血性中风模型大鼠的血浆代谢组学研究［J］.中国中药杂志,2012,37(7):1028-1033.
［14］黄郑隽, 阙慧卿, 彭华毅, 等. 雷公藤内酯醇对雄性大鼠的生殖毒性及其机制研究［J］.中国中药杂志,2015,40(23):4655-4659.
［15］Ma B, Qi H, Li J, et al. Triptolide disrupts fatty acids and peroxisome proliferator-activated receptor (PPAR) levels in male mice testes followed by testicular injury: A GC-MS based metabolomics study［J］. Toxicology, 2015,336:84-95.
［16］Patti GJ, Yanes O, Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy［J］. Nat Rev Mol Cell Biol, 2012,13(4):263-269.
［17］Xu QY, Liu YH, Zhang Q, et al. Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats［J］. Acta Pharmacol Sin, 2014,35(10):1265-1273.
［18］Yan B, A J, Wang G, et al. Metabolomic investigation into variation of endogenous metabolites in professional athletes subject to strength-endurance training［J］. J Appl Physiol (1985), 2009,106(2):531-538.
［19］徐晨, 陈维佳, 于江洪, 等. 基于液相色谱-质谱的代谢组学方法研究卷柏治疗高尿酸血症大鼠的作用机制［J］.质谱学报,2016,37(5):440-445.
［20］Aitken RJ, Whiting S, De Iuliis GN, et al. Electrophilic aldehydes generated by sperm metabolism activate mitochondrial reactive oxygen species generation and apoptosis by targeting succinate dehydrogenase［J］. J Biol Chem, 2012,287(39):33048-33060.
［21］宾彬, 陆海旺, 王杰, 等. 强精煎对奥硝唑所致少弱精子症大鼠抗氧化作用实验研究［J］.中国中医基础医学杂志,2016,22(4):484-487.

[1]	DU Caifeng, MAO Yunan, GAO Jia, WANG Juan, LI Xiaoye, TIAN Junsheng, LIU Hongqi. Research on serum metabolic markers of menopausal syndrome based on 1H-NMR metabolomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 961-968.
[2]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[3]	GAO Yan, LI Juntong, WU Qinglin, LI Lin, ZHANG Lan. Tetrahydroxy stilbene glycoside protects mice from acetaminophen-induced liver injury: study based on metabonomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 161-166.
[4]	ZHANG Haowen, ZHU Yejin, WU Xiang, CHEN Hanyu, SONG Yulei, BIAN Yaoyao, HAO Haiping, CHEN Xiaohu. Study on high on-aspirin platelet reactivity in diabetic mice based on metabonomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 246-256.
[5]	ZHANG Yongxue, HE Qing, ZHANG Xiaoyu, ZHANG Wenxin, ZHAO Qingzhong, WANG Zhiwei, GAO Shan. GC-MS-based a carrier gas purge experimental device to test the electronic smoke nicotine concentration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 776-781.
[6]	LIU Wencheng，TAN Buzhen，ZHAN Xinlu，HU Hui，HUANG Genhua，CAO Qing. Study on the cisplatin-sensitization effect of tripterygium glycosides on cisplatin-resistant human epithelial ovarian cancer cells (SKOV3/DDP) in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1364-1370.
[7]	LIU Bei, LIANG Sheng-wang. Progress of metabonomic study on cerebral ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 828-834.
[8]	YAO Wei-feng, ZHOU Li-na, ZHANG Li, DING An-wei, LI Wei. Cell Metabonomics and its Applications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 334-340.
[9]	HE Mu, YAO Wei-feng, CAI Xiu-jiang, DING An-wei, JIANG Ye-juan. Application of metabonomics in liver and kidney injury research [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 924-930.
[10]	ZHAO Chun-yan, A Ji-ye, CAO Bei, LIU Lin-sheng, WANG Xin-wen, LI Meng-jie, SHI Jian, WANG Guang-ji. Progress of metabonomic study on various metabolic diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(4): 439-446.
[11]	XIE An-yun, CHENG Ze-neng, OU-YANG Dong-sheng, GUO Xin, HUANG Zhi-jun, ZHANG Gui-xiang, LIU Chang,TAN Hong-yi,YANG Li, YANG Guo-ping. Phase Ⅰ clinical tolerability trial of (S)-ornidazole tablets [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(4): 412-416.
[12]	SHEN Shui-juan, HU Zuo-xiang, WANG Shi-ming, LI Qing-hua. Clinical curative effect observation of ambrette capsule combined with tripterygium glycosides tablet on diabetic nephropathy of IV stage [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 85-88.
[13]	HE Jun, ZHAO Chun-jing, LIAO Chang-jun, YANG Zheng, TANG Ying. Protective effects of lycopene on hepatic injury induced by tripterygium glycosides in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(10): 1096-1099.
[14]	CHENG Su-qing, GAO Hai-yan, XU Ju-fang. Clinical efficacy and safety of ornidazole vaginal effervescent tablets in the treatment of bacterial vaginitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(10): 1168-1172.
[15]	GUAN En-ze, ZHU Xuan-xuan, WANG Guang-ji, HAO Hai-ping, DING Yang. Metabonomics technology and its applications in disease diagnosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(1): 11-15.